Understanding CA 72-4: Normal vs Optimal Ranges

?What is CA 72-4?

CA 72-4 is a tumor-associated antigen used primarily as a blood marker to monitor certain cancers, particularly gastric, ovarian, and colorectal malignancies. It is produced by cancer cells and may be elevated in the presence of malignant tumors or other conditions affecting these organs. This marker is most useful for tracking treatment response and recurrence rather than as a screening tool in asymptomatic individuals.

!Why It Matters

Elevated CA 72-4 levels may suggest the presence of gastrointestinal or gynecological cancers, or could indicate cancer recurrence in patients with a history of these malignancies. Serial monitoring of this marker during and after cancer treatment can help assess treatment efficacy and detect early signs of relapse. However, CA 72-4 is not specific to cancer alone and can be associated with benign conditions, so it should always be interpreted alongside imaging and clinical evaluation.

Reference Ranges

Lab normal ranges may vary between laboratories. Optimal and longevity targets are based on research literature and should be interpreted with your physician.

Symptoms of Imbalance

• Abdominal pain or discomfort
• Persistent bloating or early satiety
• Unexplained weight loss
• Changes in bowel habits
• Vaginal bleeding or abnormal discharge

How to Improve Your Levels

• 1Follow oncologist recommendations for cancer treatment and monitoring protocols
• 2Maintain regular follow-up appointments and repeat CA 72-4 testing as scheduled
• 3Support overall health through balanced nutrition and adequate hydration
• 4Manage stress and emotional well-being during cancer treatment and recovery
• 5Avoid smoking and limit alcohol consumption
• 6Engage in gentle physical activity as tolerated and approved by your healthcare provider

When to Test

CA 72-4 should be tested in patients with a known or suspected diagnosis of gastric, ovarian, or colorectal cancer, and typically as part of baseline assessment and periodic monitoring during treatment. It is most useful for tracking disease progression in established cancer cases rather than as a standalone screening test in asymptomatic individuals.

Related Biomarkers